Seegene Launches Million-Case Clinical Study

Seegene is setting out to establish new testing standards for each disease through a large-scale global clinical study of one million cases, the first in the diagnostic industry.

Global molecular diagnostics company Seegene announced on July 8 that it will promote the ‘Global Million Clinical Study (GMCS)’ project. This project will be conducted in major countries around the world, including South Korea, starting in August, and its core is to prove the usefulness of testing strategies for each disease by securing more than one million real clinical data cases for the first time in the industry.

GMCS will verify the clinical value of ‘syndromic PCR’ based testing, which goes beyond the existing single pathogen-focused testing to simultaneously identify major causative organisms with a single test. The company plans to present a more sophisticated patient management model by analyzing hidden pathogens, co-infection status, and genotypes that were difficult to detect with conventional methods.

At the center of the research lies ‘STAgora’, a real-time diagnostic data analysis platform. The accumulated data will be linked with the platform and utilized as basic material to analyze the occurrence patterns of infectious diseases by country and disease, which will serve as a scientific basis for establishing new global testing standards in the future.

Seegene will verify the comprehensive testing strategy for major diseases such as respiratory infections (RP), sexually transmitted infections (STI), human papillomavirus (HPV), and gastrointestinal infections (GI). The company aims to objectively evaluate the value that the additionally secured clinical information contributes to actual medical decision-making by comparatively analyzing current testing methods in the medical field and the new strategy.

In particular, the company focuses on reducing diagnostic gaps caused by different medical environments and guidelines in each country. To solve the problem of patients receiving different levels of diagnosis depending on the systems of each country despite having the same disease, the concept is to establish universal and standardized global standards based on real data.

Jong-Yoon Chun, Chairman of Seegene, emphasized, “GMCS is a project that opens a new paradigm of diagnosis based on evidence from actual medical fields beyond simple data accumulation. We will not stop at developing good technology, but will continuously lay a scientific foundation so that all people around the world can receive the best testing regardless of region.”

Meanwhile, Seegene was recently selected as one of the ‘2026 World’s Most Influential Companies’ announced by the American weekly news magazine TIME.